Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14951 - 14975 of 14985 in total
Iopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned).
Investigational
Matched Description: … Iopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of
ONO-2952 is under investigation in clinical trial NCT01887002 (Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)).
Investigational
Matched Description: … ONO-2952 is under investigation in clinical trial NCT01887002 (Study to Evaluate the Effects of ONO-2952 …
Investigational
CLX-0921 is investigated for use/treatment in diabetes mellitus type 2. CLX-0921 is a solid. CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. This substance targets the protein peroxisome proliferator-activated receptor gamma. It is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity to...
Investigational
Matched Description: … CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. …
AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Investigational
SB-269970 is an experimental drug developed by GlaxoSmithKline. In the studies performed with this agent, it has been suggested that SB-269970 acts either as a selective antagonist or inverse agonist of the serotonin receptor 7 (5-HT7).[A31816,A31817]
Investigational
Matched Description: … agent, it has been suggested that SB-269970 acts either as a selective antagonist or inverse agonist of
N-methylmesoporphyrin is a solid. This compound belongs to the porphyrins. These are compounds containing a fundamental skeleton of four pyrrole nuclei united through the alpha-positions by four methine groups to form a macrocyclic structure. This medication is known to target ferrochelatase.
Experimental
Matched Description: … These are compounds containing a fundamental skeleton of four pyrrole nuclei united through the alpha-positions …
Sirpiglenastat, also known as DRP-104, is a prodrug of 6-diazo-5-oxo-L-norleucine (DON), which is a broad-acting glutamine antagonist. It is under investigation in clinical trial NCT04471415 (Study to Investigate DRP-104 in Adults With Advanced Solid Tumors).
Investigational
Matched Description: … Sirpiglenastat, also known as DRP-104, is a prodrug of [6-diazo-5-oxo-L-norleucine] (DON), which is a …
Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies. It is beneficial in treating patients with diabetic nephropathy.
Investigational
Matched Description: … Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease …
Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.[A257048,A257053]
Investigational
ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.
Investigational
Investigational
Investigational
Investigational
Investigational
Investigational
XL418 is a novel anticancer compound.
Investigational
Investigational
Investigational
Investigational
Investigational
AR-9281 inhibits soluble epoxide hydrolase.
Investigational
ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas. It is an attractive target for immunotherapy.
Investigational
Investigational
Displaying drugs 14951 - 14975 of 14985 in total